What is the main purpose of this Form 8-K filing?

The main purpose of this Form 8-K filing is to publicly announce and report BeiGene, Ltd.'s financial results for the three and nine months ended September 30, 2016. It serves as a notification to investors and the public about these financial updates.

Where can I find the actual financial details (revenue, expenses, etc.)?

The specific financial details are not fully contained within the 8-K form itself. They are provided in the press release issued by BeiGene, Ltd. on November 10, 2016, which is furnished as Exhibit 99.1 to this report.

Is this report considered 'filed' or 'furnished'?

According to the text, the information in this report and the attached press release is intended to be 'furnished,' not 'filed,' for purposes of Section 18 of the Securities Exchange Act of 1934. This means it generally does not subject the company to liabilities under that section, nor is it automatically incorporated into other filings unless specifically referenced.

What is the significance of the financial results for investors?

For investors, these financial results provide a snapshot of the company's performance during the reported period. They would typically analyze revenue, profitability (or net loss, common for biotech), cash flow, and operational expenses to assess the company's financial health, growth trajectory, and effectiveness of its business strategy, especially in the context of its drug development pipeline.

ONC/BEIGF 8-K: Earnings & Results

Summary

BeiGene, Ltd. (ONC) filed a Form 8-K on November 10, 2016, to report its financial results for the third quarter and the first nine months of 2016. This filing is primarily an announcement of these financial results, with the detailed financial information contained within an accompanying press release (Exhibit 99.1). For investors, this report serves as an update on the company's financial performance during the period ending September 30, 2016. While the 8-K itself is a notification, the furnished press release would contain the specific revenue, net income/loss, and other key financial metrics that investors would scrutinize to gauge the company's operational and financial health. As a biotechnology company likely investing heavily in research and development, investors would typically look for details on cash burn, progress in clinical trials, and any updates on their drug pipeline alongside the reported financial figures.

Key Highlights

1BeiGene, Ltd. reported its financial results for the three and nine months ended September 30, 2016.
2The report is filed under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
3The detailed financial information is provided in a press release furnished as Exhibit 99.1 to the 8-K.
4The filing date is November 10, 2016.
5The company is registered in the Cayman Islands.
6Howard Liang, CFO and Chief Strategy Officer, signed the report on behalf of BeiGene, Ltd.

BeOne Medicines Ltd. 8-K Report, Financial Results (Nov 10, 2016)

Summary

Key Highlights

Frequently Asked Questions